Search Results
Found 2 results
510(k) Data Aggregation
(261 days)
BODITECH MED INC.
AFIAS TSH-SP, for use in conjunction with the AFIAS-6/SP Analyzer, is an immunofluorometric test system intended for in vitro diagnostic use at clinical laboratories and Point-of-Care (POC) sites for the quantitative measurement of thyroid stimulating hormone (TSH) levels in serum, sodium-heparinized plasma samples. The test system is intended for use as an aid in the diagnosis of thyroid or pituitary disorders.
AFIAS-6/SP Analyzer is a fluorescence-scanning instrument for in vitro diagnostic use at clinical laboratories and Pointof-Care (POC) sites in conjunction with various in vitro diagnostic AFIAS immunoassays for measuring the concentration of designated analytes in serum or plasma samples.
AFIAS TSH-VB, for use in conjunction with the AFIAS-6/VB Analyzer, is an immunofluorometric test system intended for in vitro diagnostic use at clinical laboratories and Point-of-Care (POC) sites for the quantitative measurement of thyroid stimulating hormone (TSH) levels in sodium-heparinized or EDTA venous whole blood samples. The test system is intended for the monitoring of TSH levels in euthyroid and hypothyroid individuals.
AFIAS-6/VB Analyzer is a fluorescence-scanning instrument for in vitro diagnostic use at clinical laboratories and Pointof-Care (POC) sites in conjunction with various in vitro diagnostic AFIAS immunoassays for measuring the concentration of designated analytes in venous whole blood samples.
AFIAS TSH-SP as well as AFIAS TSH-VB Test Cartridge is a plastic structure molded in the form of a disposable, self-contained, unitized device which houses the 'lyophilized detection buffer', the 'diluent i.e. reconstitution buffer' as well as the 'test strip'; all of which are integral components of the test. The test cartridge is an elongated structure having 140 mm length. 17 mm width and 17 mm height.
'AFIAS TSH-SP ID Chip' as well as 'AFIAS TSH-VB ID Chip' is a flat, rectangular device with its main body measuring 24 mm × 20 mm × 3 mm. Another rectangular portion measuring 12 mm × 10 mm × 2 mm protrudes out from the apical side of the main body. The ID Chip is an electronic memory device fitted into a plastic matrix. Lot-specific 'ID Chip' is an integral component of the test.
AFIAS-6/SP as well as AFIAS-6/VB analyzer is a compact, bench-top, automated, fluorometric analyzer measuring 42 cm (L) x 33.6 cm (W) x 29.3 cm (H). AFIAS-6 weighs 15.1 kg. Either analyzer is a flourometer instrument of closed-system analyzer type.
Here's an analysis of the provided text, outlining the acceptance criteria and study details for the AFIAS TSH devices:
Acceptance Criteria and Device Performance for AFIAS TSH-SP and AFIAS TSH-VB
Note: The document presents acceptance criteria implicitly through performance study results and comparisons to a predicate device. Specific numerical acceptance criteria (e.g., "CV must be 0.95 or higher). | 0.9998 (Serum vs. Sodium heparin plasma), 0.9997 (Serum vs. Di-Potassium EDTA plasma) | 0.9998 (Sodium heparin venous whole blood vs. Di-Potassium EDTA venous whole blood) |
| Clinical Method Comparison (Correlation Coefficient) | High correlation (e.g., >0.95 or higher) with predicate device. | 0.9994 | 0.9999 |
| Clinical Method Comparison (Weighted Deming Regression Slope) | Close to 1 (e.g., 0.9-1.1) to indicate agreement with predicate. | 0.976 | 0.909 |
| Clinical Method Comparison (Weighted Deming Regression Y-intercept) | Close to 0 to indicate agreement with predicate. | -0.003 | 0.012 |
2. Sample Size and Data Provenance
- Limit of Blank (LoB):
- Test Set Sample Size: 5 unique blank/TSH-depleted human serum samples (for TSH-SP) and 5 unique blank/TSH-depleted whole blood samples (for TSH-VB). Each tested in 5 replicates, with 3 lots on 3 analyzers for 3 days, leading to 75 replicates per lot/analyzer.
- Data Provenance: Not explicitly stated (e.g., country). Appears to be laboratory-controlled samples (TSH-depleted).
- Limit of Detection (LoD):
- Test Set Sample Size: 5 unique low TSH-spiked human serum samples (for TSH-SP) and 5 unique low TSH-spiked whole blood samples (for TSH-VB). Each tested in 5 replicates, with 3 lots on 3 analyzers for 3 days, leading to 75 replicates per lot/analyzer.
- Data Provenance: Not explicitly stated (e.g., country). Appears to be laboratory-controlled samples (TSH-spiked).
- Limit of Quantitation (LoQ):
- Test Set Sample Size:
- TSH-SP: 5 low TSH-spiked serum samples, tested in 2 replicates daily in two runs, for 21 successive days (total 210 measurements per sample per lot/analyzer combination).
- TSH-VB: 4 low TSH-spiked venous whole blood samples, tested in 5 replicates daily in two runs, for 5 successive days (total 200 measurements per sample per lot/analyzer combination).
- Data Provenance: Not explicitly stated (e.g., country). Appears to be laboratory-controlled samples (TSH-spiked).
- Test Set Sample Size:
- Linearity and Reportable Range:
- Test Set Sample Size: 22 test samples each for TSH-SP (serum) and TSH-VB (whole blood), prepared by mixing high and TSH-depleted samples. Each tested in triplicate.
- Data Provenance: Not explicitly stated (e.g., country). Laboratory-prepared samples.
- Susceptibility to High-dose Hook Effect:
- Test Set Sample Size: 12 spiked samples (TSH concentrations 25 to 3000 µIU/ml). Tested in triplicate.
- Data Provenance: Not explicitly stated (e.g., country). Laboratory-prepared samples.
- Analytical Specificity:
- Test Set Sample Size: Samples spiked with various interferants/cross-reactants. Specific number of samples not detailed, but substances and concentrations are listed.
- Data Provenance: Not explicitly stated (e.g., country). Laboratory-prepared samples.
- Site-to-Site Precision/Reproducibility:
- Test Set Sample Size:
- TSH-SP: 4 serum samples (TSH levels ~0.5, ~5.0, ~15.0 & ~55.0 µIU/ml). Each tested in 5 replicates, with 3 lots on 3 analyzers (1 per site) by 9 operators (3 per site). Total 15 replicates per sample per site, 45 replicates per sample combined.
- TSH-VB: 4 whole blood samples (TSH levels ~0.5, ~5.0, ~15.0 & ~55.0 µIU/ml). Each tested in 5 replicates, with 3 lots on 3 analyzers (1 per site) by 9 operators (3 per site). Total 15 replicates per sample per site, 45 replicates per sample combined.
- Data Provenance: External point-of-care sites. Not explicitly stated (e.g., country). Uses clinical samples (Clinical Serum Sample 1, 2, Clinical Venous Whole Blood Sample 1, 2) and spiked samples (Spiked Serum Sample 3, 4, Spiked Venous Whole Blood Sample 3, 4).
- Test Set Sample Size:
- Matrix Comparison:
- Test Set Sample Size:
- TSH-SP: 81 matched serum vs. sodium heparin plasma samples; 79 matched serum vs. Di-Potassium EDTA plasma samples.
- TSH-VB: 63 matched sodium heparin venous whole blood vs. Di-Potassium EDTA venous whole blood samples.
- Data Provenance: Clinical samples from same study subjects. Not explicitly stated (e.g., country).
- Test Set Sample Size:
- Adult Reference Interval:
- Test Set Sample Size:
- TSH-SP: 128 apparently healthy adults (65 males, 63 females, age 21-70 years) for serum samples.
- TSH-VB: 133 apparently healthy adults (69 males, 64 females, age 21-70 years) for sodium heparin venous whole blood samples.
- Data Provenance: Not explicitly stated (e.g., country). Appears to be prospective collection of healthy adult samples.
- Test Set Sample Size:
- Clinical Method Comparison:
- Test Set Sample Size:
- TSH-SP: 183 serum samples (including 22 spiked).
- TSH-VB: 157 sodium heparinized venous whole blood samples (including 22 spiked).
- Data Provenance: Clinical sites (three point-of-care sites). Samples collected from across the three study sites. Not explicitly stated (e.g., country).
- Test Set Sample Size:
3. Number of Experts and Qualifications for Ground Truth
- The document describes in vitro diagnostic devices for measuring TSH levels. The performance studies for these types of devices primarily rely on established analytical methods and reference standards rather than expert human interpretation of images or clinical cases.
- No "experts" were used to establish ground truth in the typical sense of a diagnostic imaging study (e.g., radiologists interpreting images). Instead, ground truth is established by:
- Reference testing (e.g., predicate device, or other established laboratory methods) for method comparison studies.
- Known concentrations for spiked samples (LoD, LoQ, Linearity, Hook Effect, Analytical Specificity).
- Large cohorts of 'apparently healthy adults' for reference intervals.
4. Adjudication Method
- None specified. For in vitro diagnostic assays, ground truth is typically analytical (known concentrations, reference method results) rather than requiring adjudication of human interpretations.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
- No. This is an in vitro diagnostic (IVD) test, not an imaging device that requires human interpretation. Therefore, an MRMC study comparing human readers with and without AI assistance is not applicable. The precision study did involve multiple operators at POC sites using the device, but this is different from an MRMC study for diagnostic interpretation.
6. Standalone Performance Study
- Yes. All the analytical and clinical studies described (LoB, LoD, LoQ, Linearity, Hook Effect, Analytical Specificity, Site-to-Site Precision, Matrix Comparison, and Reference Interval determination) assess the algorithm/device performance in a standalone manner. The "human-in-the-loop" aspect is limited to the operator performing the test according to instructions, not interpreting results in a diagnostic imaging sense.
- The Clinical Method Comparison study also implicitly evaluates standalone performance by comparing the device's results to a predicate device.
7. Type of Ground Truth Used
- Known concentrations: For LoB, LoD, LoQ, Linearity, Hook Effect, and Analytical Specificity, ground truth is established by preparing samples with known or precisely characterized TSH concentrations (e.g., TSH-depleted, TSH-spiked samples).
- Predicate device results: For Clinical Method Comparison, the results from the Access Fast hTSH (on the Access 2 system) are used as the reference/ground truth for comparison.
- Statistically derived from healthy population: For Adult Reference Interval determination, ground truth is derived from the statistical distribution (2.5th and 97.5th percentiles) of TSH levels in a large cohort of apparently healthy adults.
8. Sample Size for the Training Set
- The document does not explicitly describe a "training set" in the context of machine learning or AI models, as this is an IVD device and the performance studies focus on analytical validation.
- However, the calibration process for the device (Lot-specific master calibration curve encoded in an ID chip) implies that a set of characterized samples would have been used by the manufacturer to establish these curves. The size of this internal calibration data set is not provided in this document.
9. How the Ground Truth for the Training Set Was Established
- As above, due to this being an IVD device and not an AI/ML model with a distinct "training set" in the conventional sense, this information is not explicitly provided.
- The calibration curves provided on the ID chips would have been established by the manufacturer using a reference method and a range of TSH standards/samples with known concentrations. This would involve a comprehensive analytical process to ensure accuracy and precision across the measuring range.
Ask a specific question about this device
(294 days)
Boditech Med Inc.
i-CHROMA iFOB in conjunction with i-CHROMA Reader is a fluorescence immuno-chromatographic assay system for qualitative detection of fecal occult blood (FOB) in human fecal samples.
i-CHROMA iFOB is an in vitro diagnostic test used by laboratories and physician offices for routine physical examination when gastrointestinal bleeding may be suspected.
i-CHROMA iFOB in conjunction with i-CHROMA Reader is a fluorescence immunochromatographic assay system for qualitative detection of fecal occult blood (FOB) in human fecal samples.
The provided text describes the i-CHROMA iFOB with i-CHROMA Reader device, a fluorescence immunochromatographic assay system for qualitative detection of fecal occult blood (FOB) in human fecal samples.
Here's an analysis of the acceptance criteria and the study that proves the device meets them:
1. A table of acceptance criteria and the reported device performance
The provided text does not explicitly state "acceptance criteria" as a separate section with numerical targets. Instead, performance testing results are presented as summaries. The performance is compared to a predicate device (OC Auto Micro FOB Test). The acceptance of the device is implied by its demonstrated performance in these studies, showing high agreement and accuracy with the predicate device and being "equally sensitive" to certain hemoglobin types.
Acceptance Criteria (Implied from performance summary) | Reported Device Performance (i-CHROMA iFOB) |
---|---|
No hook effect | Showed no prozone/hook effect up to analyte concentration 2000 ng/mL. |
Sensitivity to Hemoglobin S | Equally sensitive to 'Hemoglobin S' as the abnormal hemoglobin associated with sickle cell anemia. |
No significant cross-reactivity with animal hemoglobin | Showed no significant cross-reactivity with any of the eight animal hemoglobin (bovine, chicken, fish, horse/equine, goat, pig/swine, rabbit, and sheep origin). |
No significant interference from endogenous substances | No significant interference from any of the four endogenous substances (Ascorbic acid, Bilirubin, Albumin and Myoglobin). |
High repeatability and reproducibility | Showed high degree of repeatability as well as between-run, lot-to-lot, instrument-to-instrument and site-site reproducibility. |
High overall percent agreement with predicate device (analytical method comparison) | Analytical method comparison study at three US sites showed high degree of overall percent agreement as well as positive percent agreement and negative percent agreement between test results obtained with i-CHROMA iFOB and the predicate method OC Auto Micro FOB. |
High positive and negative percent agreements with predicate device (clinical testing) | More than 96% positive and negative percent agreements in test results when compared with the predicate method OC Auto Micro FOB. |
High accuracy with weak positive and weak negative samples | 95-99.66% accuracy in test results with weak positive and weak negative samples. |
2. Sample size used for the test set and the data provenance
- Analytical Method Comparison Study: "Analytical method comparison study at three US sites performed on spiked human fecal samples..." The sample size is not explicitly stated for this study, only that it was conducted at three US sites. The data provenance is US sites and involves spiked human fecal samples.
- Clinical Testing Study: "Clinical testing study at two Korean and one US site involving prospective testing of clinical human fecal samples..." The sample size is not explicitly stated for this study. The data provenance is two Korean and one US site and involves prospective testing of clinical human fecal samples.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
The document does not specify the number of experts used or their qualifications for establishing the ground truth. It primarily relies on comparison with a predicate device.
4. Adjudication method for the test set
The document does not describe any adjudication method (e.g., 2+1, 3+1) for the test set.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
This device is an automated occult blood analyzer (i-CHROMA Reader) that provides qualitative (positive/negative) results. It is not an AI-assisted diagnostic tool for human readers. Therefore, an MRMC comparative effectiveness study regarding human reader improvement with AI assistance is not applicable and was not conducted. The device acts as the "reader" itself.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
Yes, the performance studies described are for the device as a standalone system: "i-CHROMA iFOB with i-CHROMA Reader". The "i-CHROMA Reader" automatically scans the test cartridge and displays the result. There is no human-in-the-loop performance described for this qualitative test, as the device itself determines and displays the positive/negative outcome.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
The ground truth for the performance studies appears to be established by comparison with a predicate device (OC Auto Micro FOB Test). In the analytical method comparison, spiked human fecal samples were used, where the "ground truth" would be the known concentration of hemoglobin in the spiked samples. For the clinical testing study, the comparison was against the predicate method.
8. The sample size for the training set
The document does not mention a separate training set or its sample size. This device is not described as involving machine learning that would typically require a distinct training set. The device operates based on pre-programmed calibration and an analytical cut-off.
9. How the ground truth for the training set was established
Since a dedicated "training set" for a machine learning model is not mentioned, the concept of establishing ground truth for such a set is not applicable in this context. The device relies on a pre-programmed calibration, and the ID chip contains encoded calibration data for batch-to-batch variation. The establishment of this calibration data (which serves a similar purpose to informing the device's measurement accuracy) is not detailed beyond being "pre-programmed."
Ask a specific question about this device
Page 1 of 1